PMID- 11720096
OWN - NLM
STAT- MEDLINE
DCOM- 20011207
LR  - 20190701
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 69
IP  - 24
DP  - 2001 Nov 2
TI  - Effects of repeated doses of MDMA ("ecstasy") on cell-mediated immune response in 
      humans.
PG  - 2931-41
AB  - Cell-mediated immune response after the administration of two repeated doses of 
      100 mg 3,4-methylenedioxymethamphetamine (MDMA) at 4-hour and 24-hour intervals 
      was evaluated in two randomised, double-blind and cross-over clinical trials 
      conducted in healthy male MDMA consumers. MDMA produced a time-dependent decrease 
      in the CD4/CD8 T-cell ratio due to a decrease in the number of CD4 T-helper 
      cells, a decrease in the functional responsiveness of lymphocytes to mitogenic 
      stimulation, and a simultaneous increase in natural killer cells. In case of two 
      100 mg MDMA doses given 4 hour apart, immune alterations produced by the first 
      dose were strengthened by the second one. At 24 hours after treatment, 
      statistically significant residual effects were observed for all the altered 
      immune parameters after the administration of two MDMA doses if compared to 
      single dose and placebo. In the second clinical trial, the second 100 mg MDMA 
      dose given 24 hours after the first dose produced immunological changes 
      significantly greater than those induced by the initial drug administration and 
      which seemed to show a delayed onset. Significant residual effects were observed 
      for all the immune parameters as late as 48 hours after the second dose. These 
      results show that repeated administration of MDMA with both a short and a long 
      time interval between doses extends the critical period following MDMA 
      administration, already observed after a single dose, in which immunocompetence 
      is severely compromised.
FAU - Pacifici, R
AU  - Pacifici R
AD  - Clinical Biochemistry Department, Istituto Superiore di Sanita, Roma, Italy.
FAU - Zuccaro, P
AU  - Zuccaro P
FAU - Farre, M
AU  - Farre M
FAU - Pichini, S
AU  - Pichini S
FAU - Di Carlo, S
AU  - Di Carlo S
FAU - Roset, P N
AU  - Roset PN
FAU - Ortuno, J
AU  - Ortuno J
FAU - Pujadas, M
AU  - Pujadas M
FAU - Bacosi, A
AU  - Bacosi A
FAU - Menoyo, E
AU  - Menoyo E
FAU - Segura, J
AU  - Segura J
FAU - de la Torre, R
AU  - de la Torre R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Phytohemagglutinins)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - *CD4-CD8 Ratio
MH  - Cells, Cultured
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Humans
MH  - Immunity, Cellular/*drug effects
MH  - Immunophenotyping
MH  - Killer Cells, Natural/drug effects
MH  - Lymphocyte Activation/drug effects
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*adverse effects
MH  - Phytohemagglutinins/pharmacology
MH  - T-Lymphocytes, Helper-Inducer/drug effects
EDAT- 2001/11/27 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/27 10:00
PHST- 2001/11/27 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/27 10:00 [entrez]
AID - S0024-3205(01)01373-X [pii]
AID - 10.1016/s0024-3205(01)01373-x [doi]
PST - ppublish
SO  - Life Sci. 2001 Nov 2;69(24):2931-41. doi: 10.1016/s0024-3205(01)01373-x.